Proximity to blue spaces and risk of infection with Pseudomonas aeruginosa in cystic fibrosis: A case–control analysis  Pieter C. Goeminne, Tim S. Nawrot,

Slides:



Advertisements
Similar presentations
Colonisation and infection of the paranasal sinuses in cystic fibrosis patients is accompanied by a reduced PMN response  Helle Krogh Johansen, Kasper.
Advertisements

J.H.K. Hull, W. Tucker, A.G. Hatrick, R.K. Knight, T.B.L. Ho 
Cheryl Cameron, Mark W. Lodes, William M. Gershan 
Prevalence and impact on FEV1 decline of chronic methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with Cystic Fibrosis  E.
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients  R. Cantón, N. Cobos,
Colonisation and infection of the paranasal sinuses in cystic fibrosis patients is accompanied by a reduced PMN response  Helle Krogh Johansen, Kasper.
Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients  Helle Krogh Johansen, Samuel.
Is infection with hypermutable Pseudomonas aeruginosa clinically significant?  Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir 
R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J
Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort  Margaret Rosenfeld, Julia Emerson, Sharon McNamara,
Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.
J.H.K. Hull, W. Tucker, A.G. Hatrick, R.K. Knight, T.B.L. Ho 
Megan R. Nelson, Craig R. Adamski, Audrey Tluczek 
Amoxicillin–clavulanic acid resistance in fecal Enterobacteriaceae from patients with cystic fibrosis and healthy siblings  Gwen Duytschaever, Geert Huys,
Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis  M. Proesmans, F. Vermeulen,
Urinary incontinence in 9���16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group  W.J. Browne, C.J. Wood, M.
Nadav Traeger, Qiuhu Shi, Allen J. Dozor  Journal of Cystic Fibrosis 
Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study  Doug L. Forrester, Alan J. Knox,
Laura Viviani, Baroukh M. Assael, Eitan Kerem 
Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of.
A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study  Maret L. Maliniak, Arlene A.
Cirrhosis and other liver disease in cystic fibrosis
Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin 
Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection  Marita Gilljam, Henrik Scherstén, Martin Silverborn, Bodil.
Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia  P.Ø. Jensen, C. Moser, A. Kharazmi,
Non-invasive liver elastography (Fibroscan) for detection of cystic fibrosis-associated liver disease  Peter Witters, Kris De Boeck, Lieven Dupont, Marijke.
Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study  Christine Rønne.
D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams 
Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox 
Comparison of real time diagnostic chemistries to detect Pseudomonas aeruginosa in respiratory samples from cystic fibrosis patients  J.L. Fothergill,
Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn 
Implementation of European standards of care for cystic fibrosis ��� Control and treatment of infection  J.S. Elborn, M. Hodson, C. Bertram  Journal of.
A.H. Gifford  Journal of Cystic Fibrosis 
Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden  Per Kristian Knudsen, Hanne.
Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009  Yolanda P. Lillquist,
Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis  Sanja Stanojevic, Valerie Waters, Joseph L.
François Vermeulen, Marijke Proesmans, Mieke Boon, Kris De Boeck 
Characterisation of mutations and genotype–phenotype correlation in cystic fibrosis: Experience from India  Shivaram S. Shastri, Madhulika Kabra, Sushil.
Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis 
Valerie Waters, Eshetu G
E. Tschiedel, H. Grasemann, F. Ratjen  Journal of Cystic Fibrosis 
Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?
Narelle S. Cox, Jennifer Follett, Karen O. McKay 
Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis  Geraint B. Rogers, Lucas R. Hoffman,
Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic  Amanda L. Griffiths, Danielle F. Wurzel,
Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention  H. White, K. Pollard, C. Etherington, I. Clifton,
Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients  Valerie Waters, Eshetu G. Atenafu, Annie.
Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa  Karen O. McKay, Peter J. Cooper, Peter P. van.
Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005  F.A. Millar, N.J. Simmonds, M.E. Hodson  Journal.
F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal 
Comparison of two tobramycin nebuliser solutions: Pharmacokinetic, efficacy and safety profiles of T100 and TNS  Dorota Sands, Ewa Sapiejka, Grzegorz.
C. Van de Kerkhove, P. C. Goeminne, M. Kicinski, T. S. Nawrot, N
V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume 
H. White, A.M. Morton, S.P. Conway, D.G. Peckham 
J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer 
Risk factors for Mycobacterium abscessus infection in cystic fibrosis patients; a case– control study  Maarten Verregghen, Harry G. Heijerman, Monique.
C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T
D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher 
CFTR modulators and pregnancy: Our work has only just begun
‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis
Cheryl Cameron, Mark W. Lodes, William M. Gershan 
Treatment intensity and characteristics of MRSA infection in CF
Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz  Journal of Cystic Fibrosis 
Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub 
David Adeboyeku, Sandra Scott, Margaret E. Hodson 
Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)—A cause for concern? 
Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L
B. Martha, D. Croisier, A. Fanton, K. Astruc, L. Piroth, F. Huet, P
Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population  Elaine.
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience  C.R.
Presentation transcript:

Proximity to blue spaces and risk of infection with Pseudomonas aeruginosa in cystic fibrosis: A case–control analysis  Pieter C. Goeminne, Tim S. Nawrot, Kris De Boeck, Ben Nemery, Lieven J. Dupont  Journal of Cystic Fibrosis  Volume 14, Issue 6, Pages 741-747 (November 2015) DOI: 10.1016/j.jcf.2015.04.004 Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Illustration of the determination of beeline distance and shortest walking distance between home and blue spaces. Blue lines: “blue space”; White lines: roads; Red square: home address; Single arrows: shortest beeline distance options (full single arrow shows the shortest choice – 71m, dotted single arrow shows the longest of both choices – 129m); Green double arrow lines: shortest walking distance possibilities (full double arrow line shows the shortest choice — 132m; dotted double arrow lines (167 and 217m) are longer than the full line). Journal of Cystic Fibrosis 2015 14, 741-747DOI: (10.1016/j.jcf.2015.04.004) Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Map of Belgium with the location of the residence of 28 cystic fibrosis patients who were never infected by Pseudomonas aeruginosa and 28 cystic fibrosis patients with chronic colonization by P. aeruginosa: Red dots are patients who were never infected by P. aeruginosa; Green dots are patients who have chronic P. aeruginosa colonization. The dashed line is the limit between the Flemish and Walloon regions of Belgium. Journal of Cystic Fibrosis 2015 14, 741-747DOI: (10.1016/j.jcf.2015.04.004) Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Beeline distance between home and the nearest water source in 28 cystic fibrosis patients who were never infected by Pseudomonas aeruginosa and 28 cystic fibrosis patients with chronic colonization by P. aeruginosa: Horizontal lines represent mean values and standard deviation; p-value obtained by unpaired Student's t-test. Journal of Cystic Fibrosis 2015 14, 741-747DOI: (10.1016/j.jcf.2015.04.004) Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions

Fig. 4 Walking distance between home and the nearest water source in 28 cystic fibrosis patients who were never infected by Pseudomonas aeruginosa and 28 cystic fibrosis patients with chronic colonization by P. aeruginosa: Horizontal lines represent mean values and standard deviation; p-value obtained by unpaired Student's t-test. Journal of Cystic Fibrosis 2015 14, 741-747DOI: (10.1016/j.jcf.2015.04.004) Copyright © 2015 European Cystic Fibrosis Society. Terms and Conditions